Targeted Alpha Therapy with Ac-Macropa-Isatuximab for CD38-positive Hematological Malignancies
Natalia Herrero Álvarez, David Bauer, Alexa L. Michel, Lukas M. Carter, Jason Stuart Lewis
This paper evaluates [225Ac]Ac-Macropa-Isatuximab as a targeted alpha therapy for CD38-positive hematological malignancies, showing significant tumor reduction and survival extension with minimal toxicity.
bioRxiv · Nov 1, 2024 · PreprintPharmacology & Toxicology